Drug intelligence / Profile preview

SB213503

Development stage: Unknown
Administration: Intramuscular

Overview

SB213503 is a code name for an investigational compound referenced in clinical literature, specifically in the context of vaccine administration schedules. It appears in reports describing its use as part of a vaccination regimen administered at 6, 10, and 14 weeks in healthy infants. However, there is no detailed public information available regarding its chemical structure, mechanism of action, therapeutic class, or developer. The available data do not clarify whether SB213503 refers to a specific active pharmaceutical ingredient or serves as an internal study identifier for a vaccine formulation.

Beyond the preview

Go deeper on SB213503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB213503.

Explore the full profile